Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QRFPR | Q96P65 | 13/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | AHR | P35869 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL116962 | 0.87 | QRFPR (0.77) | QRFPRKCNH2CYP2D6KCNE1SCN5A | |
| SCHEMBL565379 | 0.86 | QRFPR (0.76) | QRFPRKCNH2CYP2D6KCNE1SCN5A | |
| SCHEMBL169139 | 0.81 | QRFPR (0.68) | QRFPRKCNH2CYP2D6KCNE1SCN5A | |
| SCHEMBL117974 | 0.80 | QRFPR (0.68) | QRFPRKCNH2CYP2D6KCNE1SCN5A | |
| SCHEMBL117808 | 0.77 | QRFPR (0.63) | QRFPRKCNH2CYP2D6KCNE1SCN5A | |
| SCHEMBL118802 | 0.74 | QRFPR (0.59) | QRFPRKCNH2CYP2D6KCNE1SCN5A | |
| SCHEMBL116600 | 0.74 | QRFPR (0.59) | QRFPRKCNH2CYP2D6KCNE1SCN5A | |
| SCHEMBL175520 | 0.73 | QRFPR (0.57) | QRFPRKCNH2CYP2D6KCNE1SCN5A | |
| SCHEMBL119128 | 0.73 | QRFPR (0.58) | QRFPRKCNH2CYP2D6KCNE1SCN5A | |
| SCHEMBL22004383 | 0.73 | KMT2A (0.71) | QRFPRKCNH2CYP2D6KCNE1SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035155-A1 | INDOLE-2-CARBOXAMIDE DEIVATIVE | MSD K.K. (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035155-A1 | INDOLE-2-CARBOXAMIDE DEIVATIVE | MSD K.K. (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035155-A1 | INDOLE-2-CARBOXAMIDE DEIVATIVE | MSD K.K. (JP) | 2012-02-09 | — | — | US | disclosed |
| WO-2010126164-A1 | INDOLE-2-CARBOXAMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035155-A1 | INDOLE-2-CARBOXAMIDE DEIVATIVE | HTR1F, HTR3C, HTR6 | QRFPR 11/4885KCNH2 829/4885CYP2D6 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.